ProCE Banner Activity

ZUMA-5: Phase II Study of Axicabtagene Ciloleucel in R/R Indolent Non-Hodgkin Lymphoma

Slideset Download
Conference Coverage
Axi-cel, a CD19-directed CAR T-cell therapy, produced high and durable response rates in patients with FL or MZL and ≥ 2 previous lines of therapy.

Released: December 18, 2020

Expiration: December 17, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology